Technical Data
P9052-40H
Proprotein Convertase Subtilisin Kexin 9, NT (Proprotein Convertase Subtilisin/kexin Type 9, PCSK9, FH3, Hypercholesterolemia Autosomal Dominant 3, HCHOLA3, LDLCQ1, Neural Apoptosis Regulated Convertase 1, NARC1, NARC-1, PC9, Proprotein Convertase PC9, PS
Description:
PCSK9 is a proprotein convertase belonging to the proteinase K subfamily of the secretory subtilase family. This protein is synthesized as a soluble zymogen that undergoes autocatalytic intramolecular processing in the endoplasmic reticulum. The protein may function as a proprotein convertase. The protein plays a role in cholesterol homeostasis and may have a role in the differentiation of cortical neurons.

Applications:
Suitable for use in Flow Cytometry, Immunohistochemistry and Western Blot. Other applications not tested.

Recommended Dilution:
Flow Cytometry: 1:10-1:50
Immunohistochemistry: 1:10-1:50
Western Blot: 1:1000
Optimal dilutions to be determined by the researcher.

Storage and Stability:
May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
TypeIsotypeCloneGrade
PabIgGAffinity Purified
SizeStorageShippingSourceHost
200ul-20CBlue IceHumanRabbit
Concentration:
As reported
Immunogen:
Synthetic peptide corresponding to a portion of amino acids within aa144-173 from the N-terminal region of human PCSK9 (Q8NBP7), conjugated to KLH.
Purity:
Purified by Protein A affinity chromatography.
Form
Supplied as a liquid in PBS, 0.09% sodium azide.
Specificity:
Recognizes human PCSK9.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1.Abifadel,M., Rabes,J.P. Hum. Mutat. 30(7), E682-E691 (2009). 2.McNutt,M.C., Kwon,H.J. J. Biol. Chem. 284(16), 10561-10570 (2009). 3.Shioji,K., Mannami,T. J. Hum. Genet. 49(2), 109-114 (2004). 4.Abifadel,M., Varret,M. Nat. Genet. 34(2), 154-156 (2003).